Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125245201 | 12524520 | 1 | I | 20160621 | 20160704 | 20160704 | EXP | US-CIPLA LTD.-2016US08191 | CIPLA | READY NE, DUDEK AZ, PANG HH, HODGSON LD, GRAZIANO SL, GREEN MR, ET AL.. CISPLATIN, IRINOTECAN, AND BEVACIZUMAB FOR UNTREATED EXTENSIVE-STAGE SMALL-CELL LUNG CANCER: CALGB 30306, A PHASE II STUDY. JOURNAL OF CLINICAL ONCOLOGY. 2011;29 (33):4436 TO 4441 | 0.00 | Y | 0.00000 | 20160704 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125245201 | 12524520 | 1 | PS | Irinotecan | IRINOTECAN | 1 | Unknown | 65 MG/M2, ON DAYS 1 AND 8 | U | U | 77219 | 65 | MG/M**2 | ||||||
| 125245201 | 12524520 | 2 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | 30 MG/M2, ON DAYS 1 AND 8 | U | U | 0 | 30 | MG/M**2 | ||||||
| 125245201 | 12524520 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Unknown | 15 MG/KG, ON DAY 1 AT 21 DAY INTERVALS | U | U | 0 | 15 | MG/KG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125245201 | 12524520 | 1 | Small cell lung cancer extensive stage |
| 125245201 | 12524520 | 2 | Small cell lung cancer extensive stage |
| 125245201 | 12524520 | 3 | Small cell lung cancer extensive stage |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125245201 | 12524520 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125245201 | 12524520 | Disease progression |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |